MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.phrs.2024.107560

Медицинская библиотека · Pharmacological research · 2024

A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.

Benderski Karina, Schneider Paul, Kordeves Panayiotis, Fichter Michael, Schunke Jenny, De Lorenzi Federica, Durak Feyza, Schrörs Barbara, Akilli Özlem, Kiessling Fabian, Bros Matthias, Diken Mustafa, Grabbe Stephan, Schattenberg Jörn M, Lammers Twan, Sofias Alexandros Marios, Kaps Leonard

СтатьяПеревод в очереди

Аннотация

Hepatocellular Carcinoma (HCC) is the most common form of primary liver cancer, with cirrhosis being its strongest risk factor. Interestingly, an increasing number of HCC cases is also observed without cirrhosis. We developed an HCC model via intrasplenic injection of highly tumorigenic HCC cells, which, due to cellular tropism, invade the liver and allow for a controllable disease progression. Specifically, C57BL/6JRj mice were intrasplenically inoculated with Dt81Hepa1-6 HCC cells, with a subgroup pre-treated with CCl4 to induce cirrhosis (C-HCC). At four weeks post-inoculation, mice were sacrificed, and diseased livers were analyzed via histology, flow cytometry, and RT-qPCR to profile the extracellular matrix (ECM), angiogenesis, and immune cells. In addition, tumor-bearing mice were treated with the first-line therapy, AtezoBev, to assess therapeutic responsiveness of the model. Dt81Hepa1-6 cells displayed similar gene expression as human HCC. After intrasplenic injection, all mice developed multifocal disease. C-HCC mice had a significantly higher tumor load than non-cirrhotic HCC mice. Both HCC and C-HCC models displayed extensive ECM formation, increased levels of vascularization, and immune cell infiltration compared to healthy and non-cancerous cirrhotic livers. AtezoBev treatment produced robust antitumor efficacy, validating the model's suitability for therapy testing. In conclusion, we established a rapidly developing and high-yield HCC model through a simple intrasplenic injection, with or without cirrhotic damage. The model overexpressed key human HCC genes and showed high responsiveness to first-line treatment. Our model uniquely combines all the above-mentioned features, promoting its use towards HCC therapy testing.

Для цитирования: Benderski Karina, Schneider Paul, Kordeves Panayiotis, Fichter Michael, Schunke Jenny, De Lorenzi Federica, Durak Feyza, Schrörs Barbara, Akilli Özlem, Kiessling Fabian, Bros Matthias, Diken Mustafa, Grabbe Stephan, Schattenberg Jörn M, Lammers Twan, Sofias Alexandros Marios, Kaps Leonard. A hepatocellular carcinoma model with and without parenchymal liver damage that integrates technical and pathophysiological advantages for therapy testing.. Pharmacological research. 2024. DOI: 10.1016/j.phrs.2024.107560.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.